The National Health Insurance Directory has again started to adjust, with 130 new drugs or negotiations entering, involving Roche, Hengrui...

Guide: Roche, Takeda, Hengrui and other new drugs or enter the negotiations.
evening of August 17th, the State Health Insurance Administration officially issued two documents, the Work Programme for the Adjustment of the National Health Insurance Drug Catalog 2020 and the 2020 Guidelines for the Adjustment and Declaration of the National Health Insurance Drug Catalog.
means that after a year, china's health insurance directory will start to adjust.
It is important to note that new drugs explicitly included in the programme of work need to be approved for market by 17 August 2020, unlike the "final deadline for drug marketing is 31 December 2019" mentioned in the previously published draft for comments.
The Programme states that drugs outside the drug catalogue in accordance with the provisions of Articles 7 and 8 of the Interim Measures for the Administration of Medications for Basic Medical Insurance, and in one of the following cases, may be included in the scope of new drugs to be added to the drug catalogue in 2020.
, the conditions in the third, fifth and sixth will involve innovative drugs.
in addition to the transfer-in principle, the programme describes the range of medicines transferred out of the catalogue and the requirements for adjusting payment standards.
from the timeline, the preparation phase will begin in July-August 2020, the declaration will begin in August-September 2020, the expert review in September-October 2020, the formal negotiations and bidding in October-November 2020 and the results will be announced in November-December 2020.
qualified enterprises can carry out the online declaration system on August 21-30, after which paper declaration materials can be submitted.
months, the 2020 edition of the health-care catalog will be officially released.
new drugs such as Roche, Takeda and Hengrui, or enter the negotiations in addition to the regular access section, you can see that the health care negotiations will continue, and every year.
recent years, China has been exploring and perfecting the mechanism of medical insurance negotiation.
the fourth batch of Medicare drug negotiations in November.
2019 version of the health insurance negotiations involved a total of 150 drugs, of which 119 new negotiated drugs and 31 renewal negotiation drugs, more than 70 enterprises involved, mainly for exclusive or patent period protection of high-priced varieties, the negotiated payment criteria are valid for 2 years.
97 drugs were successfully negotiated, with 70 of the new drugs negotiated and 27 in renewal negotiations, with an average price drop of 60.7 per cent.
specifically, Zhongkang CMH data show that arginine glutamate from 354 yuan / branch down to 54 yuan / branch, Adamu monosine from 7820 yuan / branch down to 1290 / branch, a decline of more than 80%.
have been successful in negotiating drugs are new ones that have been on the market in recent years, including many new ones in 2018.
, the State Drug Administration approved a total of 31 imported and domestically produced new drugs in the first half of this year.
Among the imported new drugs are Roche's Atilijuma anti-injection fluid, Takeda's injection of Vidojuma, etc., and the domestic new drug has The first domestic three-generation EGFR-TKI inhibitor mesotheli acid ometini tablets, the first original BTK inhibitor Zambetini capsules in Baiji Shenzhou, etc.
The following are the 27 new drugs (figure I) that are likely to enter the negotiating table by 2020, as well as 103 drugs that may or will enter the 2020 national health-care negotiations (by the end of 2019) (figure II).
Figure 1 Figure 2 Chart Source: GBISOURCE Database Figure 2 includes Hengrui Pharmaceutical's PD-1 product Karilijuma resistance, Alzheimer's disease drug Ganlut sodium capsules, etc., as well as the recent industry hotly debated spinal muscular dystrophy (SMA) treatment drug Nosina sodium injection.
's catalogue of health-care negotiations for 2020 looks good.
Health insurance catalog as one of the commercial ways of innovative drugs at the recent Sipp meeting, a health insurance expert pointed out that new drugs, original research drugs, etc. through health insurance access negotiations, sales, sales amount increased, shorten the time of these drugs in public hospitals, health insurance fixed-point institutions marketing time, reduce the cost of promotion.
he said the drug negotiations had identified ways in which innovative drugs would be rewarded and promoted in drug research and development.
And overall, on the one hand, with the development of volume procurement, generic drugs will end the comfort period of high gross margin, into the "small profits and more sales" model, to obtain high profits, the need for transformation and upgrading, some local enterprises began to turn to high generic drugs, innovative drugs;
there is no doubt that the health-care directory adjustment gives newly listed drugs an opportunity to improve drug access.
e.g., the PD-1, which first entered the health insurance catalog last year, was approved in December 2018, and according to December 2019 data, among the PD-1 products currently approved for domestic listing, Syndicate mono-anti-drugs are growing rapidly in the hospital market, accounting for more than 50 percent of the market.
new drug research and development investment is huge, after the introduction of the market price is naturally expensive, some life-saving terminally ill new drugs, but also sky-high prices.
whether new drugs will be included in the health insurance catalog in the future will be a compulsory course for companies to commercialize new products.
of course, in addition to the realization of health insurance release, there are many payment strategies such as early bird program, discount, special drug insurance and so on.
some industry analysts said that this year's health care negotiations may also have more new models.
to look forward to.
.